Tillomed Laboratories Limited, the European subsidiary of Emcure Pharmaceuticals Ltd, has signed an Asset Purchase Agreement (APA) with UK-based Manx Healthcare Limited and its subsidiaries, Manx Pharma Ltd. and Manx Generics Limited.
As part of the agreement, Tillomed will acquire Manx’s product portfolio, including dossiers, marketing authorizations, intellectual property, and inventory, for approximately £19.7 million. This includes an upfront payment of £6.2 million, with the remaining amount to be paid as milestone payments over the next 18 months.
This strategic acquisition will enhance Tillomed’s product offerings, expand its market presence, and strengthen its ability to meet evolving patient needs.
Commenting on the deal, Ajit Srimal, CEO of Tillomed, stated, "With Manx’s established and high-quality product portfolio, we reinforce our commitment to providing accessible healthcare solutions. This acquisition will help diversify our offerings and further solidify our market position."